Willem Pieter

Original Article Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction Van Kleef et al. #LiverX tinyurl.com/245fzwhb

Check out our new MAF-5 liver fibrosis risk score for the general population with metabolic dysfunction! This score outperforms existing scores such as FIB-4 and could be a game changer for clinical care pathways gastrojournal.org/article/S0016-… #Livertwitter @AmerGastroAssn @AGA_Gastro

#EASLStudio: 📢Anti-NASH drug expected in 2024 10%/25-30% of weight loss needed for effects on inflammation & fibrosis Semaglutide ➡️ useful as early treatment? Medications help to lose & maintain weight loss 👍Lifestyle change, combination therapy & multidisciplinary management

Fib-4 is the most widely accepted and used NIT (non-invasive test) for MASLD and MASH initial assessments. In this video fireside chat, @wpbrouwer shares the recent study presented at #easlcongress 2023: "METABOLIC DYSFUNCTION ASSOCIATED FIBROSIS-5 (MAF-5) SCORE ACCURATELY IDENTIFIES AT-RISK LIVER FIBROSIS AND PREDICTS PROGNOSIS IN A POPULATION-BASED SETTING". From the @EASLnews presentation: "The MAF-5 is a validated, age-independent, inexpensive referral tool to identify patients at high risk of liver fibrosis in the primary care setting. • It outperformed other NITs in the primary care setting especially in the younger and older populations and had a stable performance across (heterogeneous) populations • It was significantly associated with biopsy-proven fibrosis severity in NAFLD/NASH patients • MAF-5 was significantly associated with all-cause mortality • The MAF-5 score may therefore be a good alternative for the FIB-4 for use in the referral pathway for liver-health evaluation." Authors also include, Laurens van Kleef, @FrancqueSven, Jhon E. Prieto-Ortiz, Milan J. Sonneveld, Carlos B. Sanchez-Luque, Robin G. Prieto-Ortiz, Wilhelmus J. Kwanten, Luisa Vonghia, An Verrijken, Christophe De Block, Zouhir Gadi, Harry Janssen, Robert J. de Knegt.

💠This is a formidable step forward for @uegjournal ➡️Bears the signature of @KM_Pawlak 🔝work of the @my_ueg trainee editors @juliakasperUEG @dragos_ci @a_zanetto @AlexandreNuzzo @ArchibugiLivia @MelchiorChloe @Iagorlago @diogolibanio @wpbrouwer @MarcusHollenba1

Very good conference on #NAFLD and #NASH @ the #EASL #NAFLDsummit ! Rotterdam hospitals @ErasmusMC and #sintfranciscusgasthuis represented 💪🏻@EASLedu @EASLnews 📷 by @etrepo

Joining the #MAFLD debate: it’s not alcohol use that drives mortality risk in metabolic associated #fattyliver disease! doi.org/10.1002/hep.32… #livertwitter #alcohol #NAFLD #Hepatology @HEP_Journal

Great @UEGJournal editor meeting with my friends @my_ueg House in Vienna @ArchibugiLivia @KM_Pawlak @lelecapurso @wpbrouwer @diogolibanio @dragos_ci @joostphdrenth @MelchiorChloe

@UEGJournal new Journal Impact factor 4.623 @dragos_ci @a_zanetto @AlexandreNuzzo @ArchibugiLivia @MelchiorChloe @Iagorlago @diogolibanio @wpbrouwer @MarcusHollenba1 @KM_Pawlak

Post #ILC2021 session in 🇳🇱 with Ulrich Beuers ✅ Together with @UEGJournal @wpbrouwer on viral hepatitis incl #COVID19 ✅ Great joint effort on stage @my_ueg @EASLnews @phil_newsome7 @tom_marjot @ThomasBerg24 @franconegro57

Onze lieve Teun is geboren ! 12-06-21 💙💙 zoo trots! instagram.com/p/CQI9SogJwc6k…

Taking @UEGJournal to a new Twitter 🌐 Congrats to @dragos_ci @a_zanetto @AlexandreNuzzo @ArchibugiLivia @MelchiorChloe @Iagorlago @diogolibanio @wpbrouwer @MarcusHollenba1 @KM_Pawlak @my_ueg onlinelibrary.wiley.com/doi/full/10.10…

Happy to share the news that our nationwide 🇳🇱paper on 'Aggressive fluid hydration to prevent post-ERCP pancreatitis (FLUYT): a multicentre, open-label, randomised controlled superiority trial' has been accepted by @LancetGastroHep ❇️trial with 826 patients! @my_ueg

“Dual aetiology fatty liver disease”: A recently proposed term associa... sciencedirect.com/science/articl…

Episode 47 -January 2021 is out! Covering Malignant polyp recommendations, EOE in pregnancy, HE treatment, etc. #GITwitter #LiverTwitter #MedEd iTunes - cutt.ly/gipearls Spotify - cutt.ly/gipearls2 Stitcher - cutt.ly/gipearls3 Web -gipearls.com

Check out our new publication which shows an improved long-term #survival for #septic #shock patients treated with #cytosorb @CytoSorbents doi.org/10.1159/000512…

Maybe I did not advertise it well enough but....As of yesterday @KM_Pawlak is the Social Media Editor of @UEGJournal I have great confidence that she will exceed all expectations @wpbrouwer @drkeithsiau @AlexandreNuzzo @Iagorlago @diogolibanio @MelchiorChloe @Iagorlago

I have great trust in @wpbrouwer & Marcus Hollenbach acting as Search Engine Optimization Editors for @UEGJournal They will do the job and your article in will find its way among the best of the best @dragos_ci @AlexandreNuzzo @MelchiorChloe @Iagorlag @diogolibanio @my_ueg

Inaugural meeting with the @my_ueg trainee editors @WileyEducation Very happy to have these excellent professionals attached to the @UEGJournal @wpbrouwer @KM_Pawlak @AlexandreNuzzo @Iagorlago @diogolibanio

CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock - Sep 25, 2019 cytosorbents.mediaroom.com/2019-09-25-Cyt…